BioWorld - Tuesday, February 25, 2025
See today's BioWorld
To read the full story, subscribe or sign in.

STATute of limitations? Time running out for ‘undruggable’ SH2 as Recludix bags $60M series A

Nov. 15, 2021
By Randy Osborne
No Comments
Recludix Pharma Inc. launched with a $60 million series A round to target Src homology 2 (SH2) domains, and the new money will get the San Diego-based firm to reach the IND-enabling stage, CEO Nancy Whiting told BioWorld.
BioWorld Financings Cancer Inflammatory Series A